-

Circle Pharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced that management will participate in two upcoming investor conferences:

Morgan Stanley 23rd Annual Healthcare Conference
1X1 Meetings: Monday, September 8, 2025
Location: New York, NY

Oppenheimer Life Sciences Private Company Showcase
1X1 Meetings: Thursday, September 25, 2025
Location: Virtual

About Circle Pharma

Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.

Contacts

Media:
Josie Butler
1AB
josie@1abmedia.com

Investors:
Steve Klass
1AB
steve@1abmedia.com

Industry:

Circle Pharma, Inc.

Release Versions
English

Contacts

Media:
Josie Butler
1AB
josie@1abmedia.com

Investors:
Steve Klass
1AB
steve@1abmedia.com

More News From Circle Pharma, Inc.

Circle Pharma Strengthens Leadership Team with Promotion of Marie Evangelista, Ph.D., to Chief Scientific Officer and Addition of Mary Ellen Sillivos as SVP and Head of Human Resources

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the promotion of Marie Evangelista, Ph.D., to chief scientific officer and the appointment of Mary Ellen Sillivos as senior vice president and head of human resources. The appointments strengthen Circle’s leadership team as the company advances its pipeline of next-generation targeted macrocycle ther...

Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an oversubscribed $92.5 million Series E financing. The financing was led by The Column Group and included participation from other existing and new investors including Nextech Invest, RA Capital Management, Euclidean Capital and Eli Lilly and Company. Proceeds from the financing will drive the advan...

Circle Pharma to Present New Clinical and Preclinical Data at AACR 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting April 17-22 in San Diego....
Back to Newsroom